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Abstract: Suppressors of Cytokine Signaling (SOCS) inhibit Signal Transducers and Activators of Transcription
(STATs) phosphorylation by binding and inhibiting Janus Kinases (JaKs). The aim of the present study was to
evaluate the influence of glucocorticosteroids on the JaK/STAT signaling pathway in the leukocytes of nephrotic
syndrome (NS) patients. The study group was composed of 34 steroid sensitive NS (SSNS) children and 20
steroid resistant NS (SRNS) subjects. Gene expression was assessed by real-time PCR using pre-designed hu-
man JaK/STAT PCR array. Protein expression was evaluated using ELISA assay (plasma concentration) and
immunofluorescence (in situ protein expression). In SSNS children, the initial increased expression of JaK1,
JaK2, JaK3, STAT1, STAT2, STAT6, TYK2, SOCS1, SOCS2, SOCS3, SOCS4 and SOCS5 was reduced back to
the control limits. Similarly, in SRNS patients the increased levels of almost all mRNA expressions for the
abovementioned genes were decreased, with the exceptions of SOCS3 and SOCS5 expressions. These mRNA
expressions were still significantly increased and correlated with early unfavorable course of nephrotic syn-
drome in children. Plasma levels of SOCS3, SOCS5, IL-6 and IL-20 were significantly increased in SRNS sub-
jects after six weeks of steroids medication compared to SSNS and control participants. We conclude that SOCS3
and SOCS5 increased mRNA expressions might predict initial resistance to steroids in NS patients. (Folia His-
tochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 719–728)
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Introduction
Nephrotic syndrome (NS) is a complex and non-spe-
cific disease characterized by severe proteinuria
(> 3.5 g/day), hypoproteinemia, generalized edema,
hyperlipidemia and, occasionally, hypertension [1].
Generally, NS base might reflect multiple immunolog-
ical disorders [2], a critical filtration barrier breakage
or could follow diabetes mellitus [3, 4], obesity [5], sar-
coidosis [6] as well as different malignancies [7, 8].
Regardless of its primary or secondary cause, the
gold standard in the induction of NS therapy is the
administration of glucocorticosteroids (GCS) [1].
GCS-dependent suppression of both cell-mediat-
ed and humoral immunity is already well established in
NS [9]. On the other hand, GCS influence all types of
inflammatory events, no matter what their cause. One
of the most interesting GCS impacts is that of JaK/STAT
signaling pathway suppression in NS patients.
The JaK-STAT system is a major signaling path-
way alternative to the second messenger transmission
[10]. It directs information from chemical signals out-
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side the cell, through the cell membrane, and into gene
promoters on the DNA in the cell nucleus, which caus-
es DNA transcription and activity in the cell [10]. The
JaK/STAT system consists of three main components:
a receptor, a Janus Kinase (JaK) membrane receptor
protein, and a Signal Transducer and Activator of
Transcription (STAT) which transduces the signal
from the receptor-JaK complex to the DNA in the
cell nucleus. JaKs, which have tyrosine kinase activity,
bind to some cell surface cytokine receptors. The bind-
ing of the ligand to the receptor triggers activation of
JaKs. With increased kinase activity, they form phos-
phorylate tyrosine residues on the receptor and create
sites for interaction with proteins (i.e. STATs) that con-
tain a phosphotyrosine-binding SH2 domain [11].
The pathway is negatively regulated on multiple
levels. Protein tyrosine phosphatases remove phos-
phates from cytokine receptors as well as activated
STATs [10]. More recently identified Suppressors of
Cytokine Signaling (SOCS) inhibit STAT phosphory-
lation by binding and inhibiting JaKs or competing
with STATs for phosphotyrosine binding sites on cy-
tokine receptors. STATs are also negatively regulat-
ed by Protein Inhibitors of Activated STATs (PIAS),
which act in the nucleus through several mechanisms
[10, 12].
Interestingly, GCS are indicated as an essential
part of the inductive treatment in all NS patients, in-
cluding subjects in whom NS is the result of some-
thing other than immune disorders [1, 9]. The lack of
effective response to GCS enables physicians to iden-
tify a group of patients with definitive resistance to
steroids (steroid resistant NS, SRNS) and perform
additional laboratory tests (i.e. biopsy of the kidney,
DNA sequencing) to estimate the non-immunologi-
cal base of the disorder.
The question is whether the abovementioned sub-
sequent analyses could be executed earlier. Is it pos-
sible to select a leukocyte genes pattern predicting
resistance to steroids or the presence of key muta-
tions, regardless of NS type? Recently, a very few
mechanisms have been proposed by which activation
of JaK/STAT signaling might be involved in the pro-
gression of glomerular diseases with proteinuric state.
They have been reported both in an animal model
[13] and in humans [14]. Nakajima et al. suggested an
overload proteinuria could activate inflammatory cas-
cades as well as oxidative stress and, in part, activate
JaK/STAT signaling pathway in renal proximal tubular
cells in vitro [14]. On the other hand, hypoalbuminemia
has been reported to cause an overexpression of SOCS
family in peripheral white blood cells [11].
The aim of the present study was to: (1) evaluate
GCS influence on the JaK/STAT signaling pathway
in the segregated leukocytes of all NS patients; and
(2) try to separate a gene pattern recruited from the
JaK/STAT system which might predict resistance to
steroids.
Material and methods
Patients. The study group was composed of children diag-
nosed with NS, who were treated between 2008 and 2010 in
the Department of Pediatric Cardiology and Nephrology,
Poznan University of Medical Sciences. One hundred and
fifty-five children were referred to our clinic, and evidence
of proteinuria was found in 78 of them. Ten subjects were
excluded from the study because at least one of the follow-
ing criteria was present: (1) age < 3 yr or > 18 yr, (2) end
stage renal disease, (3) administration of erythropoetin, (4)
administration of granulocyte colony stimulating factor or
(5) multi-drug therapy influencing immunological system.
Thirty-four patients (19 boys and 15 girls), following Inter-
national Study for Kidney Diseases in Children (ISKDC)
recommendations, underwent a biopsy [15]. The indications
included: SRNS (n = 20) and secondary glomerulonephri-
tis (n = 14, who were excluded from further analysis). Ac-
cording to World Health Organization definitions [15, 16],
histological evaluation revealed: minimal change disease
(MCD), n = 6; diffuse mesangial proliferation (DMP),
n = 5; and focal segmental glomerulosclerosis (FSGS), n = 9.
Taken together, the study group comprised 54 subjects:
34 patients — steroid sensitive nephrotic syndrome (SSNS
— no kidney biopsy performed) and 20 children with a di-
agnosis of SRNS. SSNS was defined as an absence of all NS
symptoms in those patients who reached remission with ste-
roid therapy alone. On the other hand, those patients in
whom remission was not achieved within eight weeks of ste-
roid therapy were labeled as SRNS subjects [16, 17]. The
relevant data is presented in Table 1.
The Ethics Committee of Poznan University of Medical
Sciences approved the research protocol and the parents of all
study participants gave informed consent for the investigation.
Treatment protocol. Standard ISKDC regime for the first
NS episode included administration of prednisolone —
60 mg/m2/day in three divided doses for four weeks followed
by 40 mg/m2/day in a single dose on every alternate day for
four weeks [17]. After a six week period of medication, when
proteinuria and decreased serum albumin level were still
found to be present, progressive steroid cancellation was
performed and the introduction of other immunosuppres-
sive drugs (cyclosporine, cyclophosphamide, mycopheno-
late mofetil) was recommended. The relevant data is sum-
marized in Table 1.
Controls. Ten age- and sex-matched children with a nor-
mal renal function and urinalysis who were hospitalized
in our university due to surgical reasons served as a con-
trol group.
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Blood samples and isolation of peripheral leukocytes. Blood
was sampled directly into EDTA-anticoagulated tubes. It
was collected from all the patients comprising the study
(n = 54) and control (n = 10) groups. Plasma was directly
isolated and stored at –80°C for analysis of albumins, lipids,
CRP, glucose, creatinine, and urea, using routine laborato-
ry methods. It was also assayed for the presence of biologi-
cally active SOCS3, SOCS5, IL-6 and IL-20 using the ELISA
technique. Glomerular filtration rate was calculated using
the Schwartz formula [18].
Isolation of mononuclear cells. Ten milliliters of EDTA
blood were centrifuged at 1,250 × g for 90 s to separate
cells from the platelet-rich plasma. The mononuclear cells
(monocytes and lymphocytes) were isolated on a Ficoll (Fi-
coll separating solution density 1.077; 17-1440-02; Amer-
sham Ficoll-Paque) adhering to the manufacturer’s instruc-
tions. Monocytes were consecutively isolated using indirect
magnetic labeling system using biotinylated antibody against
CD68 (MACS®, Miltenyi Biotec, Krakow, Poland). Non-
-monocytes i.e. lymphocytes (T cells, natural killer cells,
B cells and dendritic cells) as well as basophilic granulocytes
were indirectly magnetically labeled using a mixture of bi-
otinylated antibodies against CD3, CD7, CD16, CD19,
CD56, CD123, glycophorin A, and Anti-Biotin MicroBeads
(MACS®, Miltenyi Biotec). Since lymphocytes formed the
majority of non-monocytic mononuclear cells, we refer to
this fraction as lymphocytes.
Blood from all the patients was sampled twice. Firstly,
at the time of diagnosis — i.e. before treatment commence-
ment, and secondly, after a six-week period of GCS medi-
cation. It was performed to enable comparison of gene ex-
pression variation during GCS treatment and set a diagnos-
tic gene expression pattern in SSNS and SRNS study par-
ticipants.
Quantitative PCR. RNA was isolated using TRIzol® (Gib-
co, Invitrogen, Carlsbad, CA, USA) [19]. One microgram
of RNA was respectively reverse transcribed (iScript®
cDNA synthesis Kit, Bio-Rad) to cDNA.
Gene expression was assessed by real-time PCR (Ep-
pendorf, Poznan, Poland) using pre-designed human JaK/
/STAT Signaling Pathway PCR array (Sabiosciences, Qiagen,
Wroclaw, Poland). The array represented all known JaK and
STAT family members, the receptors that activate them,
nuclear co-factors and co-activators associated with the
STAT proteins, STAT-inducible genes, and negative regula-
tors of the pathway (Table 2; the complete list of studied
genes is also available at www.sabiosciences.com/
/rt_pcr_product/HTML/PAHS-039A.html).
Expression of each target gene in each subject was nor-
malized to endogenous controls GAPDH+18S (DCT) and
related to a reference (DDCT), being RNA from untreated
peripheral blood leukocytes of the controls.
ELISA reagents. The following colorimetric ELISA kits were
used in the study: (1) SOCS-3 human ELISA system,
ABIN366182 (antibodies-online GmbH, Aachen, Germa-
ny); (2) SOCS-5 human ELISA system, ABIN 422766 (an-
tibodies-online GmbH); (3) human high sensitivity IL-6
Table 1. Clinical and biochemical characteristics of the study population at the beginning of treatment
Characteristics Study population
SSNS — subgroup 1 SRNS — subgroup 2
Number of patients 34 20
Age (years) 10.5 (4–16) 11.3 (4–17)
Male/female 18/16 11/9
Proteinuria [mg/kg/24 h] 44.0 ± 12.0 92.0 ± 33.0*
Erythrocyturia (% of patients) 23.5 20.0
GFR [ml/min/1.73 m2] 97.0 ± 7.0 89.0 ± 7.0
Serum albumin [g/dl] 3.0 ± 0.7 2.3 ± 0.8*
CRP [mg/dl] < 0.5 < 0.5
Creatinine [mg/dl] 0.9 ± 0.2 0.8 ± 0.2
Urea [mg/dl] 25 ± 6.0 29 ± 8.0
Lipids [mg/dl] 158 ± 25 165 ± 21
Cholesterol [mg/dl] 182 ± 25 201 ± 24
WBC total [G/l] 5.6 ± 1.2 5.7 ± 2.3
Lymphocyte (% of WBC) 28.0 ± 12.0 32.0 ± 16.0
SSNS — steroid sensitive nephrotic syndrome; SRNS — steroid resistant nephrotic syndrome; erythrocyturia — number of red blood cells in
urine > 2 cell per high power field; GFR — glomerular filtration rate; CRP — c reactive protein; WBC — white blood cells count;
*statistical significance (p < 0.05)
722 D Ostalska-Nowicka et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0096
www.fhc.viamedica.pl
ELISA Kit, ab46042 (Abcam, Cambridge, UK); (4) human
IL-20 ELISA Kit, ABIN415142 (antibodies-online GmbH).
Biological assay for SOCS3, SOCS5, IL-6 and IL-20. De-
frosted supernatants were again clarified by centrifugation
(4,000 rpm for 2 min) and than assayed for the presence of
biologically active SOCS3, SOCS5, IL-6 and IL-20. The
following steps of ELISA were performed according to the
manufacturer’s instructions. The estimation of an average
SOCS3, SOCS5, IL-6 and IL-20 concentrations in each pa-
tient from both study (before and after GCS medication)
and control groups were founded on double cytokine eval-
uation by reading in a spectrophotometer at 450 nm.
Immunohistochemistry. In order to demonstrate SOCS3
and SOCS5 expressions in certain isolated smeared mono-
nuclear cells, an indirect immunocytochemical procedure
was performed. The endogenous activity of peroxidase was
blocked by 30 min pre-incubation in 3% hydrogen perox-
ide. The immunofluorescence investigation was based on
the initial incubation with anti-SOCS3 (diluted 1:10; rabbit
polyclonal anti-human; ab16030, Abcam) and anti-SOCS5
Table 2. Functional gene grouping in human JaK/STAT Signaling Pathway PCR Array (according to
http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-039A.html)
No. Group Analyzed genes
1 JaKs JaK1, JaK2, JaK3, TYK2
2 STAT family STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6
3 Receptors that bind CSF1R, CSF2RB, EGFR, EPOR, F2R, GHR, IFNAR1, IFNGR1, IL10RA,
and activate JaK proteins IL2RA, IL2RG, IL4R, IL6ST, INSR, MPL, PDGFRA, SH2B1
4 SH3/SH2 adaptor protein activity SH2B2 (APS), CRK, SIT1, SLA2, SRC, STAM
5 STAT protein nuclear translocation F2, F2R, STAT1
6 Tyrosine phosphorylation of STAT protein F2, F2R, IL20, PPP2R1A, PRLR, STAT1
7 Transcription factors or regulators that Positive regulation of transcription: HMGA1, SMAD3
interact with STAT proteins Negative regulation of transcription: SLA2, SMAD3, SPI1, STAT3
RNA Polymerase II transcription factor activity: JUNB, SP1, USF1
Transcription coactivator activity: JUNB, YY1
Transcription corepressor activity: JUNB, PIAS1, YY1
Transcriptional activator activity: SMAD1, SMAD5, SP1
Other transcription factors and regulators: CEBPB, CRK, GATA3, IRF1,
ISGF3G, JUN, MYC, NFKB1, NR3C1, PPP2R1A, SMAD2, SMAD4
8 Genes induced by STAT proteins Stat1: CXCL9, IRF1, JUNB, NOS2A
Stat3: A2M, BCL2L1, CDKN1A, CRP, FAS (TNFRSF6), IRF1, MMP3, MYC, SOCS1
Stat4: FCGR1A, IFNG, IRF1, MYC
Stat5: CCND1, CDKN1A, IL2RA, IRF1, OSM
Stat6: FCER1A, GATA3, IL4, IL4R
Stat1/Stat1/p48: GBP1
Stat1/Stat2/p48: ISG15 (G1P2), OAS1
9 Negative regulators of the JaK/STAT pathway PIAS1, PIAS2, PTPN1, PTPRC, SOCS1, SOCS2, SOCS3, SOCS4, SOCS5
10 Apoptosis BCL2L1, CDKN1A, F2, F2R, FAS (TNFRSF6), IL2RA, NFKB1, PPP2R1A,
PRLR, STAT1
11 Cell differentiation IL20, IL4, NOS2A, PPP2R1A, SOCS2, SOCS5
12 Cell growth and/or maintenance Cell cycle: CCND1, CDKN1A, EGFR, F2, F2R, IL2RA, IRF1, JaK2, MYC,
PPP2R1A, STAT1
Cell growth: A2M, EGFR, GHR, IFNG, IL4, INSR, OSM, PPP2R1A, SOCS1,
SOCS2, SOCS3, SOCS4, SOCS5
Cell proliferation: CSF1R, IL2RG, IL4, MPL, OSM, PDGFRA, SMAD3
13 Immune response Acute-phase response: CEBPB, CRP, F2, STAT3
Antigen processing: FCER1A, FCGR1A, PPP2R1A
Humoral immune response: SH2B2 (APS), CSF1R, CSF2RB, IL4, NFKB1, YY1
Inflammatory response: CEBPB, CRP, CXCL9, IL10RB, IL20, NFKB1,
NOS2A, NR3C1
Lymphocyte activation: IL4, PRLR, SIT1, SLA2
Other genes involved in the immune response: CXCL9, FAS (TNFRSF6),
ISG15 (G1P2), GBP1, IFNG, IL2RA, IL2RG, IL4, IL4R, IL6ST, IRF1, ISGF3G,
OAS1, OSM, STAT5A, STUB1
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(diluted 1:10; rabbit polyclonal anti-human; ab3695, Abcam)
at 4°C overnight, followed by goat anti-rabbit Alexa Fluor
555 secondary antibody (A-21429; diluted 1:200; Molecular
Probes, MobiTec, Goettingen, Germany) at 37°C for 30 min.
These reactions were observed using an Olympus BX60 mi-
croscope. Photographs were taken using a CCD camera
connected to a soft-imaging analysis system (Soft Imaging
System, Olympus, Muenster, Germany). Both analyses were
performed blind on coded samples.
Based on the results of the hematological staining, which
were analyzed using MicroImage (Olympus) morphomet-
ric software, the content of reaction-positive cells was de-
termined by comparing the number of immunopositive cells
to the total number of nucleated cells. A percentage of pos-
itive cells of < 5% was classified as a negative result.
Statistical analysis. The analysis was performed blind on
coded samples. Continuous or interval-related variables
were expressed as mean ± SD. Data was compared using
Student’s t-test, or one-way analysis of variance test (ANOVA)
where appropriate. The analysis of different gene expressions
among the study participants for assessing whether two inde-
pendent samples of observations have equally large values,
were exercised using Mann–Whitney U test (Wilcoxon–
Mann–Whitney test). A general method of alpha adjustment
for all the multiple comparisons performed in the study was
Bonferroni correction. Statistical analysis of quantitative
genes expression pattern was performed using web-based RT2
Profiler™ PCR Array Data Analysis software available at
www.sabiosciences.com/pcrarraydataanalysis.php (Sabio-
sciences).
This integrated web-based software package for the PCR
Array System automatically performed all DDCt based fold-
change calculations from uploaded raw threshold cycle data;
p < 0.05 was considered as statistically significant [20].
Results
Clinical observation
In the subsequent analysis and discussion, the term
‘study group’ refers to all 54 study participants who
were analyzed prior to commencement of the treat-
ment. During the study protocol, 34 subjects respond-
ed to steroids (SSNS patients) and 20 children had
no positive response to steroids (SRNS subjects).
SSNS and SRNS children were consequently defined
as subgroup 1 and subgroup 2 respectively.
Before treatment commencement, all the patients
comprising subgroups 1 and 2 did not differ accord-
ing to basic biochemical values (concentration of cre-
atinine, urea, lipids and cholesterol); they had a sim-
ilar white blood cells count, percentage of lympho-
cytes in peripheral blood as well as c-reactive protein
(CRP) and glomerular filtration rate (GFR) levels.
Similarly, the percentage of subjects with erythrocy-
turia was comparable. The only significant difference
referred to serum albumin concentration (3.0 ± 0.7
mg/dl vs. 2.3 ± 0.8 mg/dl in subgroups 1 and 2 respec-
tively; p < 0.05) and proteinuria (44 ± 12 mg/kg/24 h
vs. 92 ± 33 mg/kg/24 h; p < 0.05).
After the six-week period of medication, pro-
teinuria and decreased serum albumin level were still
present in subgroup 2. This resulted in renal biopsy
performance, progressive steroid cancellation and
introduction of other immunosuppressive drugs (cy-
closporine, cyclophosphamide, mycophenolate
mofetil). The relevant data is summarized in Table 1.
Expression of JaK/STAT system components in
peripheral monocytes and lymphocytes
The JaK/STAT signaling pathway expression in cir-
culating leukocytes (monocytes and lymphocytes) of
all the patients comprising the study group was ana-
lyzed twice: once before treatment commencement
and again, after six weeks, when the response to ste-
roid treatment enabled differentiation of SSNS from
SRNS subjects. The results of the initial analysis were
compared to mRNA expression in the control group
(Table 3). This allowed us to separate the list of ‘gene
— candidates’ including: JaK1, JaK2, JaK3, STAT1,
STAT2, STAT6, TYK2, SOCS1, SOCS2, SOCS3,
SOCS4 and SOCS5. Interestingly, mRNA expression
of all these genes had increased more than ten-fold
compared to the controls and did not differ between
monocyte and lymphocyte populations. The rest of
the analyzed genes (as described in ’Methods’) did
not differ significantly compared to the controls’
mRNA expression and were excluded from subse-
quent study.
The results of the second analysis of the above-
mentioned ‘gene — candidates’ were statistically
compared to the initial resistance to steroids as
well as compared between SSNS and SRNS pa-
tients (Table 3). In SSNS children (subgroup 1),
the initial increased expression of all the ‘gene —
candidates’ was reduced back to the control lim-
its. Similarly, in SRNS patients (subgroup 2) the
increased levels of almost all mRNA expressions
for ‘gene — candidates’ were decreased, except
for SOCS3 and SOCS5 expressions. Expression of
SOCS3, but not SOCS5, was increased in circu-
lating monocytes of subgroup 2 patients versus
subgroup 1 subjects (p = 0.0005). In contrast, ex-
pression of SOCS5, but not SOCS3, was increased
in lymphocytes of SRNS patients vs. SSNS study
participants (p = 0.0086). These mRNA expres-
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Table 3. Expression of ‘gene — candidates’ of JaK/STAT signaling pathway in peripheral leukocytes of children compri-
sing the study (subgroups 1 and 2) and control groups at the time of diagnosis and after six-week steroid treatment
Gene Gene expression variation
Study group at Subgroup 1 at Subgroup 2 at Subgroup 1 after
the time of diagnosis the time of diagnosis the time of diagnosis 6-week treatment
vs. controls   vs. after 6-week vs. after 6-week vs. Subgroup 2 after
treatment treatment 6-week treatment
Expression p Expression p Expression p Expression p
alteration alteration alteration alteration
JaK1 22.3 (≠) 0.0006 28.3 (Ø) 0.0004 29.1 (Ø) 0.0005 4.7 (Ø) NS
JaK2 12.8 (≠) 0.0052 12.8 (Ø) 0.0048 17.4 (Ø) 0.0086 3.8 (Ø) NS
JaK3 27.1 (≠) 0.002 13.8 (Ø) 0.0042 16.3 (Ø) 0.0038 8.6 (Ø) NS
STAT1 19.4 (≠) 0.0016 21.6 (Ø) 0.0035 14.9 (Ø) 0.0018 9.2 (Ø) NS
STAT2 48.1 (≠) < 0.0001 34.1 (Ø) 0.0001 32.3 (Ø) 0.0001 7.4 (Ø) NS
STAT6 11.3 (≠) 0.0079 15.9 (Ø) 0.0174 15.8 (Ø) 0.0086 6.6 (Ø) NS
TYK2 17.5 (≠) 0.0413 21.6 (Ø) 0.0064 16.3 (Ø) 0.0058 3.7 (Ø) NS
SOCS1 24.8 (≠) 0.0413 14.7 (Ø) 0.0064 12.1 (Ø) 0.0214 8.2 (Ø) NS
SOCS2 26.1 (≠) 0.0027 32.9 (Ø) 0.0018 16.2 (Ø) 0.0024 7.4 (Ø) NS
SOCS3 32.7 (≠) 0.0021 29.1 (Ø) 0.0005 2.4 (≠) NS 22.5 (≠) 0.0005
SOCS4 18.3 (≠) 0.0005 28.8 (Ø) 0.0006 29.3 (Ø) 0.0004 3.9 (Ø) NS
SOCS5 19.6 (≠) 0.0085 22.7 (Ø) 0.0086 3.5 (≠) NS 13.6 (≠) 0.0086
Expression alteration — times of gene expression value alteration; ≠ — increase of gene expression; Ø — decrease of gene expression;
NS — not significant
sions have also correlated to the evidences of pro-
teinuria and decreased serum albumin in the neph-
rotic syndrome patients.
Moreover, SOCS3 and SOCS5 expressions were
significantly increased in all SRNS patients after the
six-week period of GCS medication, regardless of the
histological type of the glomerulopathy (MCD, DMP
or FSGS). SOCS3 as well as SOCS5 expressions did
not differ significantly among MCD, DMP or FSGS
subjects at the beginning of the treatment or after the
six-week steroid administration.
Expression of other genes involved in the
immune response and cell differentiation in
peripheral monocytes and lymphocytes
Since JaK/STAT signaling pathway PCR array repre-
sented not only known JaK and STAT family mem-
bers, the receptors that activate them and nuclear co-
factors and co-activators associated with the STAT
proteins, but also STAT-inducible genes as well as
genes involved in the immune response, we were able
to reliably analyze the expression of a focused panel
of the abovementioned genes.
SSNS children and control patients did not reveal
increased expression of any other genes as listed in
the paragraph above. However, SRNS patients, both
before treatment commencement and after the six-
week period of GCS administration, performed a sig-
nificantly higher expression of IL-20, IL-4R, IL-6ST
and several transcription factors: JUN, MPL, MYC,
SP1 and SRC. The level of their expression did not
differ significantly in SRNS subjects during the study
protocol.
IL-20 and all the transcription factors were ex-
pressed exclusively in circulating monocytes. On the
other hand, IL-4R and IL-6ST were expressed both
in circulating monocytes and lymphocytes and the
level of their expression did not differ between the
groups.
Interestingly, IL-20, IL-4R, IL-6ST, JUN, MPL,
MYC, SP1 and SRC expressions did not differ signif-
icantly among MCD, DMP or FSGS subjects at the
beginning of the treatment or after six-week steroid
administration. Detailed information is summarized
in Table 4.
Increased plasma concentrations of SOCS3,
SOCS5, IL-6 and IL-20 in SRNS and SSNS
patients before GCS medication
Plasma levels of SOCS3, SOCS5, IL-6 and IL-20 were
significantly increased both in SRNS and SSNS chil-
dren before GCS medication compared to control
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participants. The average plasma SOCS3 concentra-
tion in these subjects was 4.8 ± 2.9 pg/ml and 5.2 ±
± 2.5 respectively (p < 0.001 as compared to controls).
The average plasma SOCS5 concentration in SRNS
patients equalled 6.6 ± 4.2 pg/ml and in SSNS chil-
dren 6.1 ± 1.8 pg/ml (p < 0.0001 as compared to con-
trols). IL-6 was also significantly increased in SRNS
and SSNS study participants and was estimated at an
average level of 8.8 ± 5.3 pg/ml and 10.2 ± 5.2 pg/ml
respectively (p < 0.0001 as compared to controls).
Finally, average IL-20 plasma concentration was es-
timated at the level 6.2 ± 4.3 pg/ml in SRNS patients
and 16.5 ± 3.2 pg/ml in SSNS children (p < 0.005
comparing SRNS to SSNS; p < 0.0001 comparing
SSNS to controls). This information is presented in
Figure 1.
Increased plasma concentrations of SOCS3,
SOCS5, IL-6 and IL-20 in SRNS patients
after six-week GCS medication
Plasma levels of SOCS3, SOCS5, IL-6 and IL-20 were
significantly increased in SRNS subjects after six-week
GCS medication compared to SSNS and control par-
ticipants.
The average plasma SOCS3 concentration in
SRNS subjects was 4.3 ± 0.6 pg/ml (p < 0.05 com-
pared to SSNS subjects after six-week GCS treatment;
p < 0.0001 compared to controls).
The average plasma SOCS5 concentration in
SRNS patients equalled 6.2 ± 2.1 pg/ml (p < 0.05
compared to SSNS subjects after six-week GCS treat-
ment; p < 0.0001 compared to controls).
IL-6 was also significantly increased in SRNS study
participants and was estimated at the average level of
2.3 ± 0.4 pg/ml (p < 0.05 compared both to SSNS
subjects after six-week GCS medication and controls.
Finally, an average IL-20 plasma concentration
was estimated at the level 17.2 ± 5.0 pg/ml (p < 0.0001
compared to SSNS study participants and controls).
This data is summarized in Figure 2.
Immunohistochemical evaluation of SOCS3
and SOCS5 in isolated monocytes
and lymphocytes
Immunocytochemical expressions of SOCS3 and
SOCS5 were performed on the smears comprising
isolated blood mononuclear cells but not segregated
into monocytes and lymphocytes. Identification of
both populations of cells (monocytes and lympho-
cytes) was based on the size of the cells: monocytes
were defined as cells of a diameter ranging from 15
to 20 μm. The rest of the cells, with an average diam-
eter not exceeding 12 μm, were regarded as lympho-
cytes. SOCS3 expression was identified exclusively in
the monocyte population (Figure 3). Indirect immu-
nofluorescence assay indicated the linear binding of
SOCS3 in the monocyte cytoplasm. SOCS3 expres-
sion was not detected in lymphocytes (Figure 3). On
the other hand, SOCS5 expression was detected in
the lymphocyte population (Figure 4). A strong gran-
Table 4. Expression of IL-20, IL-4R, IL-6ST, JUN, MPL, MYC, SP1 and SRC in peripheral leukocytes of children compri-
sing the study (subgroups 1 and 2) and control groups at the time of diagnosis and after six-week steroid treatment
Gene Gene expression variation
Study group at Subgroup 1 at Subgroup 2 at Subgroup 1 after
the time of diagnosis the time of diagnosis the time of diagnosis 6-week treatment
vs. controls   vs. after 6-week vs. after 6-week vs. controls
treatment treatment
Expression p Expression p Expression p Expression p
alteration alteration alteration alteration
IL-20 0.8 (≠) NS 0.4 (≠) NS 167.8 (≠) < 0.0001 172.1 (≠) < 0.0001
IL-4R 2.1 (≠) NS 1.9 (≠) NS 34.5 (≠) < 0.0001 67.3 (≠) < 0.0001
IL-6ST 1.1 (≠) NS 1.3 (≠) NS 16.9 (≠) < 0.0001 12.9 (≠) < 0.0001
JUN 1.9 (Ø) NS 1.1 (Ø) NS 109.2 (≠) < 0.0001 121.5 (≠) < 0.0001
MPL 1.6 (Ø) NS 0.9 (Ø) NS 99.8 (≠) < 0.0001 78.3 (≠) < 0.0001
MYC 0.3 (≠) NS 0.5 (≠) NS 110.7 (≠) < 0.0001 119.3 (≠) < 0.0001
SP1 0.8 (Ø) NS 0.6 (Ø) NS 39.2 (≠) < 0.0001 38.2 (≠) < 0.0001
SRC 0.9 (≠) NS 1.3 (≠) NS 32.7 (≠) < 0.0001 29.7 (≠) < 0.0001
Expression alteration — times of gene expression value alteration; ≠ — increase of gene expression; Ø — decrease of gene expression;
NS — not significant
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Figure 4. Suppressors of Cytokine Signaling 5 (SOCS5)
evaluated by indirect immunofluorescence in a seven year-
-old SRNS child. The strong granular pattern of SOCS5
covering the territory of the nucleus is detected in the whole
cytoplasm of lymphocyte population; scale bar: 20 μm
Figure 3. Expression of Suppressors of Cytokine Signaling 3
(SOCS3) evaluated by indirect immunofluorescence in a nine
year-old SRNS child. Notice a linear binding of SOCS3 antibodies
within the cytoplasm of a single monocyte; scale bar: 20 μm
Figure 1. Plasma concentration of SOCS3, SOCS5, IL-6
and IL-20 in steroid resistant (SRNS) and steroid sensitive
(SSNS) patients before glucocorticosteroids (GCS)
medication
Figure 2. Plasma concentration of SOCS3, SOCS5, IL-6
and IL-20 in steroid resistant (SRNS) and steroid sensitive
(SSNS) patients after six-week glucocorticosteroids (GCS)
medication
ular pattern of SOCS5 binding, covering also the ter-
ritory of the nucleus, was detected in the whole lym-
phocyte cytoplasm.
Discussion
The question as to what causes nephrotic syndrome
in children still remains open. Is the syndrome most-
ly related to immunological disorders and subsequent
filtration barrier breakage, or does it follow gene
mutations and glomerular protein modifications
which result in increased glomerular permeability?
Should we prioritize DNA sequencing in all the neph-
rotic syndrome patients to optimize medication costs
and decrease steroid side-effects in those subjects in
whom they seem to have no therapeutic effect?
The results of the present study reveal the immu-
nological shift in leukocyte JaK/STAT signaling path-
way expression in NS patients. JaK1, JaK2, JaK3,
STAT1, STAT2, STAT6, TYK2, SOCS1, SOCS2,
SOCS3, SOCS4 and SOCS5 mRNA expression val-
ues were increased more than ten-fold in all the stud-
ied patients. This certainly does not mean that all the
study participants developed NS secondary to immu-
nological system alterations.
In our opinion, immunological variations may be
secondary or appear prior to protein modification in
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the filtration barrier. Analyzing the JaK/STAT sys-
tem before the commencement of treatment cannot
anticipate the outcome. However, when the subse-
quent gene expression profile is performed after the
steroid inductive treatment (usually, it appears be-
tween the sixth and the eighth weeks of treatment
course) one could see a significant difference be-
tween SSNS and SRNS children. At this moment of
disease process, JaKs, STATs as well as TYK2, SOCS1,
SOCS2 and SOCS4 expressions are reduced to con-
trol limits. The only gene alterations are restricted
to SOCS3 and SOCS5 expressions, exclusively in
SRNS patients. Interestingly, SOCS3 and SOCS5
altered expressions in these subjects could be proved
both on mRNA and protein levels. It is also followed
by significantly increased IL-6 plasma expression in
SRNS patients.
SOCS3 has now been shown to be a key regula-
tor for the divergent activity of IL-6 and IL-20
(a member of IL-10 family) following toll-like re-
ceptor (TLR) stimulation [21]. IL-6 is a pro-inflam-
matory cytokine that assumes a progressive role in
many inflammatory diseases including nephrotic syn-
drome; while IL-20, produced by activated mono-
cytes, regulates proliferation and differentiation of
other monocytes and lymphocytes [21]. In addition,
IL-20 causes cell expansion of multipotential he-
matopoietic progenitor cells [21].
SRNS subjects, as demonstrated in the present
report, revealed a significantly higher plasma expres-
sion of both IL-6 and IL-20 after six weeks of steroid
treatment. It corresponded not only to the higher
SOCS3 and SOCS5 expressions in circulating mono-
nuclear cells, but also followed a significant loss of
protein subsequent to the filtration barrier failure.
Our observations seem to prove that overload pro-
teinuria might activate not only inflammatory cas-
cades as well as oxidative stress and, in part, JaK/STAT
signaling pathway in renal proximal tubular cells [14],
but also in selected peripheral white blood cells.
Moreover, SOCS3 protein is strongly induced by
both IL-6 and IL-10 in the presence of lipopolysac-
charide (LPS), but IL-6 signaling is selectively inhib-
ited due to the binding of SOCS3 to the IL-6ST sub-
unit gp130 (Tyr759), but not to the IL-10 receptor
(IL-10R). Modulation of the gp130/JaK/STAT path-
way therefore represents a reasonable strategy for new
anti-inflammatory drug development [21].
Little is known about SOCS5 function. When over-
expressed, SOCS5 suppresses IL-6 and leukemia in-
hibitory factor-induced signaling, although to a less-
er extent than SOCS1 or SOCS3 [22]. Human SOCS5
is expressed in many tissues, including the heart, brain,
placenta, and skeletal muscle, but its expression is
especially high in lymphoid organs such as the spleen,
lymph nodes (LN), thymus, and bone marrow (BM)
[23], indicating that SOCS5 might play a role in lym-
phocyte development or function. Recently, SOCS5
was reported to be a potential regulator of IL-4 sig-
naling [24], an effect mediated through an SH2 do-
main-independent interaction between SOCS5 and
the IL-4 receptor a chain.
The problem of JaK/STAT system signification in
nephrotic syndrome pathophysiology has not been
widely discussed in the literature. Individual publica-
tions suggest activation of JaK/STAT signaling is in-
volved in the progression of glomerular diseases with
proteinuric state [11]. These studies, however, were
performed on an animal model and took advantage
of only a few genes, including JaK2, STAT1 and
STAT3.
In line with the above, it seems that initial steroids
administration in all types of NS is still desirable. Even
if NS was following a primary filtration barrier fail-
ure resulting from gene mutations, it is accompanied
by over-expression of JaK/STAT system. Steroids are
then expected to put a brake on the immunological
response and prepare a background for the introduc-
tion of other immunosuppressive drugs.
In SRNS patients, the hypothetical effect, de-
scribed above, might be secondary to a persistent non-
immunological breakage of the filtration barrier (i.e.
an overload proteinuria secondary to gene mutations).
In our opinion, SOCS3 and SOCS5 increased
mRNA expressions not only may predict initial resis-
tance to steroids in pediatric nephrotic syndrome
patients, but also should justify more detailed molec-
ular investigations, including DNA sequencing.
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